Part 2 of phase III study of binimetinib and encorafenib produces positive top-line result

Neoadjuvant pembrolizumab helps shrink tumors in patients with desmoplastic melanoma

In a recent multi-institutional clinical trial, 71% of patients who received the immunotherapy drug pembrolizumab, an anti-PD-1 immune checkpoint inhibitor, before surgery had no detectable cancer remaining at the time of surgery.

February 06, 2026

Vol.52 No.05

Clinical Roundup

Itismeran autogene + Keytruda demonstrated improvement in recurrence-free survival in neoadjuvant melanoma

Moderna and Merck announced median five-year follow-up data from the phase IIb KEYNOTE-942/mRNA-4157-P201 study, evaluating intismeran autogene (mRNA-4157 or V940), an investigational mRNA-based individualized neoantigen therapy, in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with high-risk melanoma (stage 3/4) following complete resection.

January 30, 2026

Vol.52 No.04

Clinical Roundup

Nanoparticle vaccine prevents melanoma, pancreatic, and breast cancers in mice, study finds

A study led by University of Massachusetts Amherst researchers demonstrates that their nanoparticle-based vaccine can effectively prevent melanoma, pancreatic, and triple-negative breast cancer in mice.

October 17, 2025

Vol.51 No.38

Drugs & Targets

FDA approves Libtayo for adjuvant treatment of cutaneous squamous cell carcinoma

FDA approved cemiplimab-rwlc (Libtayo) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation.

October 10, 2025

Vol.51 No.37

Clinical Roundup

IO Biotech’s vaccine misses on mPFS in phase III advanced melanoma trial

Cylembio (imsapepimut and etimupepimut, adjuvanted), an off-the-shelf therapeutic cancer vaccine, plus pembrolizumab narrowly missed on its primary endpoint of progression free survival for patients with unresectable or metastatic melanoma, according to phase III trial results.

September 05, 2025

Vol.51 No.32

Clinical Roundup

Nivolumab + relatlimab improve survival in advanced melanoma, MD Anderson study shows

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87% of patients with stage 3 melanoma remained alive, according to new results from a study led by researchers at the University of Texas MD Anderson Cancer Center.

July 18, 2025

Vol.51 No.28

Part 2 of phase III study of binimetinib and encorafenib produces positive top-line result

YOU MAY BE INTERESTED IN

Neoadjuvant pembrolizumab helps shrink tumors in patients with desmoplastic melanoma

Itismeran autogene + Keytruda demonstrated improvement in recurrence-free survival in neoadjuvant melanoma

Nanoparticle vaccine prevents melanoma, pancreatic, and breast cancers in mice, study finds

FDA approves Libtayo for adjuvant treatment of cutaneous squamous cell carcinoma

IO Biotech’s vaccine misses on mPFS in phase III advanced melanoma trial

Nivolumab + relatlimab improve survival in advanced melanoma, MD Anderson study shows

Renew today!

Subscriber content

Never miss an issue!

Login